Lucida Medical appoints Chief Operating Officer to drive global growth
Lucida Medical, a Cambridge University spin off advancing the prostate cancer pathway through AI, announces the appointment of Robin Barclay as Chief Operating Officer.
Lucida Medical raises £8.7m to power ‘same day’ cancer diagnosis
IW Capital has invested in Lucida Medical, a UK-based healthtech company using AI to help clinicians diagnose prostate cancer from MRI scans faster and more accurately.
AI matches the accuracy of expert radiologists to detect prostate cancer in a major multi-centre clinical study
Lucida Medical and Hampshire Hospitals NHS Foundation Trust announce the results of a 5-year collaboration. The PAIR-1 study shows that the Pi AI software, now in use in NHS and European hospitals, is the first commercial product of its kind with performance equivalent to that of expert radiologists to detect prostate cancer, the most common cancer in men.
Appointment of new Vice President of Sales and Marketing at Lucida Medical
We are pleased to announce the appointment of Corina Cucuruzac as Vice President of Sales and Marketing at Lucida Medical, effective immediately. With a distinguished career in the MedTech industry across various fields, Corina brings deep expertise in driving growth, building strong customer relationships, and leading successful commercial strategies.
Lucida Medical and Hampshire Hospitals NHS Foundation Trust announce major study on AI for prostate cancer
Lucida Medical Ltd, the Cambridge-based start-up, and Hampshire Hospitals NHS Foundation Trust (HHFT), have initiated a ground-breaking, collaborative multi-centre research project. This is the first retrospective study in the UK to validate the use of AI to help identify prostate cancer using real-world data from a range of hospitals and scanner types. It will demonstrate the potential of this…